Latest Depression News

Page 5 of 14
Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.
Ada Torres
Ada Torres
27 Feb 2026
Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.
Ada Torres
Ada Torres
26 Feb 2026
TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.
Ada Torres
Ada Torres
24 Feb 2026
Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.
Ada Torres
Ada Torres
17 Feb 2026
Emyria has secured expanded funding from Medibank to support its Treatment-Resistant Depression and PTSD programs at a new clinic in Victoria, marking a significant step in its national mental health care rollout.
Ada Torres
Ada Torres
16 Feb 2026
Meridian Energy’s January 2026 report reveals robust hydro and wind generation amid record rainfall and soaring electricity demand, despite wholesale prices plunging to historic lows.
Maxwell Dee
Maxwell Dee
13 Feb 2026
Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.
Ada Torres
Ada Torres
11 Feb 2026
Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.
Ada Torres
Ada Torres
2 Feb 2026
Actinogen Medical’s pivotal XanaMIA trial for Alzheimer’s disease has received a green light from its independent Data Monitoring Committee to continue, reinforcing confidence in the drug’s safety and efficacy profile.
Ada Torres
Ada Torres
30 Jan 2026
TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.
Ada Torres
Ada Torres
30 Jan 2026
InhaleRx Limited has progressed its clinical trials for three drug candidates targeting cancer pain, panic disorder, and treatment-resistant depression, while securing additional funding and preparing for a company rebrand.
Ada Torres
Ada Torres
29 Jan 2026
Syrah Resources delivered a record quarter with a 34% rise in natural graphite production and advancing anode material qualification at its Vidalia facility, while navigating evolving US trade policies that could reshape its market dynamics.
Maxwell Dee
Maxwell Dee
28 Jan 2026

Browse the archive

Full archive